Jump to content

Runcaciguat

From Wikipedia, the free encyclopedia
Runcaciguat
Legal status
Legal status
  • Investigational
Identifiers
  • (3S)-3-[4-Chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC23H22Cl2F3NO3
Molar mass488.33 g·mol−1
3D model (JSmol)
  • C[C@H]([C@@H](C1=CC=C(C=C1)Cl)C(=O)NC2=C(C=CC(=C2)[C@@H](CC(=O)O)C3CC3)Cl)C(F)(F)F
  • InChI=1S/C23H22Cl2F3NO3/c1-12(23(26,27)28)21(14-4-7-16(24)8-5-14)22(32)29-19-10-15(6-9-18(19)25)17(11-20(30)31)13-2-3-13/h4-10,12-13,17,21H,2-3,11H2,1H3,(H,29,32)(H,30,31)/t12-,17+,21+/m1/s1
  • Key:NCRMKIWHFXSBGZ-CNBXIYLPSA-N

Runcaciguat is a soluble guanylate cyclase stimulator developed by Bayer for non-proliferative diabetic retinopathy and chronic kidney disease.[1][2][3]

References

[edit]
  1. ^ Bénardeau, Agnès; Kahnert, Antje; Schomber, Tibor; Meyer, Jutta; Pavkovic, Mira; Kretschmer, Axel; Lawrenz, Bettina; Hartmann, Elke; Mathar, Ilka; Hueser, Joerg; Kraehling, Jan R.; Eitner, Frank; Hahn, Michael G.; Stasch, Johannes-Peter; Sandner, Peter (December 2021). "Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease". Naunyn-Schmiedeberg's Archives of Pharmacology. 394 (12): 2363–2379. doi:10.1007/s00210-021-02149-4. PMC 8592982. PMID 34550407.
  2. ^ Hahn, Michael G.; Lampe, Thomas; El Sheikh, Sherif; Griebenow, Nils; Woltering, Elisabeth; Schlemmer, Karl-Heinz; Dietz, Lisa; Gerisch, Michael; Wunder, Frank; Becker-Pelster, Eva-Maria; Mondritzki, Thomas; Tinel, Hanna; Knorr, Andreas; Kern, Armin; Lang, Dieter; Hueser, Joerg; Schomber, Tibor; Benardeau, Agnes; Eitner, Frank; Truebel, Hubert; Mittendorf, Joachim; Kumar, Vijay; van den Akker, Focco; Schaefer, Martina; Geiss, Volker; Sandner, Peter; Stasch, Johannes-Peter (13 May 2021). "Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)". Journal of Medicinal Chemistry. 64 (9): 5323–5344. doi:10.1021/acs.jmedchem.0c02154. PMID 33872507. S2CID 233311492.
  3. ^ Nelissen, Ellis; Possemis, Nina; Van Goethem, Nick P.; Schepers, Melissa; Mulder-Jongen, Danielle A. J.; Dietz, Lisa; Janssen, Wiebke; Gerisch, Michael; Hüser, Jörg; Sandner, Peter; Vanmierlo, Tim; Prickaerts, Jos (4 March 2022). "The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms". Scientific Reports. 12 (1): 3589. Bibcode:2022NatSR..12.3589N. doi:10.1038/s41598-022-07391-1. ISSN 2045-2322. PMC 8897390. PMID 35246566.